Impact of obesity on hospitalized patients

Mount Sinai Journal of Medicine

Volumn 75, Issue 5, 2008, Pages 454-459

  Markoff, Brian ^a   Amsterdam, Alison ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Hospitalized patient; Metabolism; Mobility; Nutrition; Obesity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM ANTIBIOTIC; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CARBAPENEM DERIVATIVE; CARVEDILOL; DAPTOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; HEPARIN; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; METFORMIN; ORAL ANTIDIABETIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; VERAPAMIL;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL EXAMINATION; DECUBITUS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INFECTION; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MINIMUM INHIBITORY CONCENTRATION; NUTRITIONAL STATUS; OBESITY; PATIENT MOBILITY; RISK FACTOR; SIDE EFFECT; SKIN CARE; STROKE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-INFECTIVE AGENTS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; BODY MASS INDEX; DIABETES MELLITUS; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; OBESITY; PATIENT DISCHARGE; PHYSICAL EXAMINATION; RENAL DIALYSIS; RESPIRATORY FUNCTION TESTS;

EID: 57149084271     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20072     Document Type: Article

References (69)

1. Obesity and overweight. Available at: http://www.who.int/mediacentre/ factsheets/fs311/en. Accessed January 2008.
2. Wannamethee G, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health 2005; 59: 134-139.
3. Thompason D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med 1999; 159: 2177-2183.
4. Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a retrospective study. Obes Res 2001; 9: 210-218.
5. Gallagher SM. Meeting the needs of the obese patient. Am J Nurs 1996; 91: S1-S12.
6. Nowbar S, Bukart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcomes. Am J Med 2004; 116: 1-7.
7. Roth JL, Kushner RF, Bateman E. Nutritional support of the obese patient. Curr Gastroenterol Rep 2005; 7: 329-335.
8. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001; 19: 667-674.
9. Sandernick GU, Le Liboux A, Jariwala, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72: 308-318.
10. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics: a preliminary study. Eur J Clin Pharmacol 2000; 56: 293-297.
11. Foley K, Lee RB. Surgical complications of obese patients with endometrial cancer. Gynecol Oncol 1990; 39: 171-174.
12. Braden BJ, Bergstrom N. Clinical utility of the Braden scale for predicting pressure sore risk. Decubitus 1989; 2: 44-51.
13. Mathison CJ. Skin and wound care challenges in the hospitalized morbidly obese patient. J Wound Ostomy Continence Nurs 2003; 30: 78-83.
14. Terry M, O'Brien SP, Kerstein MD. Lower-extremity edema: evaluation and diagnosis. Wounds 1998; 10: 118.
15. Hahler B. Morbid obesity: a nursing care challenge. Dermatol Nurs 2002; 14: 249-256.
16. Bergstrom N, Bennett MA, Carlson CE, et al. Treatment of Pressure Ulcers. Rockville, MD: US Department of Health and Human Services; 1994.; Clinical Practice Guideline 15; AHCPR Publication 95-0652.
17. Gallagher SM. Restructuring the therapeutic environment to promote care and safety for the obese patient. J Wound Ostomy Continence Nurs 1999; 26: 292-297.
18. Gallagher SM. Caring for the obese patient. Nursing 1998; 28: 32hn1-32hn3.
19. Gallagher SM. Meeting the needs of the obese patient. Am J Nurs 1996; 96: S1-S12.
20. Gallagher S, Gates J. Challenges of ostomy care and obesity. Ostomy Wound Manage 2004; 50: 38-40.
21. Colwell JC, Fichera A. Care of the obese patient with an ostomy. J Wound Ostomy Continence Nurs 2005; 32: 378-383.
22. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572.
23. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
24. Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987; 147: 1725-1728.
25. Grassi G, Cattaneo BM, Seravalle G, et al. Obesity and the sympathetic nervous system. Blood Press 1996; 1(suppl): 43-46.
26. Samuelsson O, Hedner T, Berglund G, et al. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens 1994; 8: 257-263.
27. De Courten M, Ferrari P, Schneider M, et al. Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol 1993; 44: 457-462.
28. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
29. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
30. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994; 3: 185-188.
31. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue reninangiotensin system. Hypertension 2000; 35: 1270-1277.
32. Sharma AM, Pischon T, Engeli S, Scholze, J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2000; 19: 667-674.
33. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
34. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081-1091.
35. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997; 25: 112-118.
36. Bearden DT, Rodvold KA. Dose adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000; 38: 415-426.
37. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl): 338S-400S.
38. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978-980.
39. Heizmann M, Baerlocher GM, Steinmann F, et al. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res 2002; 106: 179-181.
40. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005; 15: 1368-1374.
41. Kroon C, De Boer A, Kroon JM, et al. Influence of skinfold thickness on heparin absorption. Lancet 1991; 337: 945-946.
42. Nicolaides AN, Harbourne T, Russell RCG. Subtaneous heparin, plasma heparin levels and postoperative wound haematoma. Br J Surg 1984; 71: 62-64.
43. Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 2003; 13: 249-253.
44. Balant L. Clinical pharmacokinetics of sulfonylurea hypoglycaemic drugs. Clin Pharmacokinet 1981; 6: 215-241.
45. Jaber LA, Antal EJ, Slaughter RL, Welshman IR. The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. Eur J Clin Pharmacol 1993; 45: 459-463.
46. Jaber JA, Ducharme MP, Halapy H. The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. Ther Drug Monitor 1996; 18: 6-13.
47. Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacokinet 2004; 38: 30-35.
48. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Pharmacol 2005; 60: 469-476.
49. Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynecol Obstet 2005; 88: 84-88.
50. Uppot RN, Sahani DV, Hahn PF, et al. Effect of obesity on image quality: fifteen-year longitudinal study for evaluation of dictated radiology reports. Radiology 2006; 240: 435-439.
51. Uppot RN. Impact of obesity on medical imaging. Radiol Clin North Am 2007; 188: 433-440.
52. Bae KT, Tao C, Gürel S, et al. Effect of weight and scanning duration on contrast enhancement during pulmonary multidetector CT angiography. Radiology 2007; 242: 582-589.
53. Burgstahler C, Beck TA, Reimann A, et al. Image quality and diagnostic accuracy of 16-slice multidetector computed tomography for the detection of coronary artery disease in obese patients. Int J Obes 2005; 30: 569-573.
54. Kussmaul WG, Bowers B, Dairywala I. Method for coronary angiography in morbidly obese patients. Catheter Cardiovasc Interv 2005; 65: 268-270.
55. McNulty PH, Ettinger SM, Field JM, et al. Cardiac catheterization in morbidly obese patients. Catheter Cardiovasc Interv 2002; 56: 174-177.
56. Unterborn J. Pulmonary function testing in obesity, pregnancy, and extremes of body habitus. Clin Chest Med 2001; 22: 759-767.
57. Crapo RO, Kelly TM, Elliott CG, Jones SB. Spirometry as a preoperative screening test in morbidly obese patients. Surgery 1986; 99: 763-768.
58. Plumb TJ, Adelson AB, Groggel GC, et al. Obesity and hemodialysis vascular access failure. Am J Kidney Dis 2007; 50: 450-454.
59. Vassalotti JA, Falk A, Cohl ED, et al. Obese and nonobese hemodialysis patients have a similar prevalence of functioning arteriovenous fistula using pre-operative vein mapping. Clin Nephrol 2002; 58: 211-214.
60. Choban PS, Flancbaum L. Nourishing the obese patient. Clin Nutr 2000; 19: 305-311.
61. Choban PS, Burge JC, Scales D, Flancbaum L. Hypoenergetic nutrition support in hospitalized obese patients: a simplified method for clinical application. Am J Clin Nutr 1997; 66: 546-550.
62. Roth JL, Kushner RF, Bateman E. Nutritional support of the obese patient. Curr Gastroenterol Rep 2005; 7: 329-335.
63. Shikora SA, Jensen GL. Hypoenergetic nutrition support in hospitalized obese patients. Am J Clin Nutr 1997; 66: 679-680.
64. Zizza C, Herring AH, Stevens J, Popkin BM. Length of hospital stay among obese individuals. Am J Public Health 2004; 94: 1587-1591.
65. de Pablo P, Losina E, Phillips CB, et al. Determinants of discharge destination following elective total hip replacement. Arthritis Rheum 2004; 51: 1009-1017.
66. Vincent HK, Weng JP, Vincent KR. Effect of obesity on inpatient rehabilitation outcomes after total hip arthroplasty. Obesity 2007; 15: 522-530.
67. Vincent HK, Vincent KR, Lee LW, Alfano AP. Effect of obesity on inpatient outcomes following total knee arthroplasty. Clin Rehabil 2007; 21: 182-190.
68. Yaegashi M, Jean R, Zurigat M, et al. J Intensive Care Med 2005; 20: 147-154.
69. Taggart HM, Mincer AB, Thompson AW. Caring for the orthopaedic patient who is obese. Orthop Nurs 2004; 23: 204-210.